Drugs

, Volume 63, Issue 15, pp 1565–1577 | Cite as

Long-Term Complications of Chemotherapy for Germ Cell Tumours

Review Article

Abstract

Testicular cancer is the most common solid tumour among young males aged 15–35 years. Cisplatin-based combination chemotherapy has changed the outlook of this disease. Disseminated testicular cancer, once uniformly fatal, now has a cure rate of more than 80% with combination chemotherapy. Systematic randomised trials have shown that cisplatin, etoposide and bleomycin (PEB) combination chemotherapy remains the mainstay of treatment. While there is a high cure rate with chemotherapy in patients with this disease, some long-term complications from chemotherapy have now been recognised, including secondary leukaemia, therapy-related solid tumours, nephrotoxicity, neurotoxicity, pulmonary toxicity, vascular toxicity and infertility.

Etoposide, a DNA topoisomerase II inhibitor, is a significant risk factor for developing leukaemia; the risk appears to be correlated with the total dose given. Patients receiving cisplatin-based combination chemotherapy for testicular cancer also appear to have a higher relative risk for developing second non-germ cell malignancies; the greatest risks for therapy-related solid tumours were seen with a combination of radiation therapy plus chemotherapy.

Long-term vascular toxicities associated with chemotherapy include Raynaud’s phenomenon, acute myocardial infarction and cerebrovascular events. Bleomycin is thought to be the most important drug in the pathogenesis of Raynaud’s phenomenon, while cisplatin is the most likely agent involved in myocardial infarction.

Peripheral neuropathy is the most common form of neurotoxicity observed with cisplatin-based chemotherapy. Risk factors for the development of neural damage include a high cumulative dose of cisplatin, the use of vinblastine and the concomitant development of Raynaud’s phenomenon. Cisplatin is also well known to cause significant nephrotoxicity.

Approximately 25% of patients present with azoospermia after undergoing combination chemotherapy with a follow up of 2–5 years.

Physician awareness of complications associated with chemotherapy is vital to maximise efficacy, minimise toxicity, and preserve quality of life after treatment. Sperm cryopreservation should be considered for patients who desire children. Close monitoring during therapy allows for the early diagnosis of complications, and close follow up of patients after the completion of therapy is necessary to monitor for relapse and development of long-term complications such as myelodysplastic syndrome and leukaemia. Despite these complications, given the potential for cure rates in this young group of patients, the benefits far outweigh the risks.

Notes

Acknowledgements

The authors have provided no information on sources of funding or on conflicts of interest directly relevant to the content of this review.

References

  1. 1.
    Small EJ, Torti FM. Testes. In: Abeloff MD, editor. Clinical oncology. New York: Churchill Livingstone, 1995: 1494Google Scholar
  2. 2.
    Donohue JP, Rowland RG. Complications of retroperitoneal lymph node dissection. J Urol 1981; 125: 338–40PubMedGoogle Scholar
  3. 3.
    Donohue JP, Thornhill JA, Foster RS, et al. The role of retroperitoneal lymphadenectomy in clinical stage B testicular cancer: the Indiana university experience (1965 to 1989). J Urol 1995; 153: 85–9PubMedCrossRefGoogle Scholar
  4. 4.
    Loehrer PJ, Williams SD, Einhorn LH. Testicular cancer: the quest continues. J Natl Cancer Inst 1988; 80: 1373–82PubMedCrossRefGoogle Scholar
  5. 5.
    Samuels ML, Lanzotti VJ, Holoye PY, et al. Combination chemotherapy in germinal cell tumors. Cancer Treat Rev 1976; 3: 185–204PubMedCrossRefGoogle Scholar
  6. 6.
    Einhorn LH, Donohue J. Cis-diamminedichloroplatinum, vinlastine, and bleomycin combination chemotherapy in disseminated testicular cancer. Ann Intern Med 1977; 87: 293–8PubMedGoogle Scholar
  7. 7.
    Bosl GJ, Gluckman R, Geller NL, et al. VAB-6 an effective chemotherapy regimen for patients with germ cell tumors. J Clin Oncol 1986; 4: 1493–9PubMedGoogle Scholar
  8. 8.
    Fitzharris BM, Kaye SB, Saverymuttu S, et al. VP16-213 as a single agent in advanced testicular tumors. Eur J Cancer 1980; 16: 1193–7PubMedCrossRefGoogle Scholar
  9. 9.
    Williams SD, Birch R, Einhorn LH, et al. Treatment of disseminated germ-cell tumors with cisplatin, bleomycin and either vinblastine or etoposide. N Engl J Med 1987; 316: 1435–40PubMedCrossRefGoogle Scholar
  10. 10.
    Baniel J, Foster RS, Rowland RG, et al. Complications of postchemotherapy retroperitoneal lymph node dissection. J Urol 1995; 153: 979–80Google Scholar
  11. 11.
    Coogan CL, Hejase MJ, Wahle GR, et al. Nerve sparing postchemotherapy retroperitoneal lymph node dissection for advanced testicular cancer. J Urol 1996; 156: 1656–8PubMedCrossRefGoogle Scholar
  12. 12.
    International germ cell consensus classification: a prognostic factor-based staging system for metastatic germ cell cancers. J Clin Oncol 1997; 15: 594–603Google Scholar
  13. 13.
    Einhorn LH, Williams SD, Loehrer PJ, et al. Evaluation of optimal duration of chemotherapy in favorable-prognosis disseminated germ cell tumors: a southeastern cancer study group protocol. J Clin Oncol 1989; 7: 387–91PubMedGoogle Scholar
  14. 14.
    Bosl GJ, Geller NL, Bajorin D, et al. A randomized trial of etoposide + cisplatin versus vinblastine + bleomycin + cisplatin + cyclophosphamide + dactinomycin in patients with good prognosis germ cell tumors. J Clin Oncol 1988; 6: 1231–8PubMedGoogle Scholar
  15. 15.
    De Wit R, Wilkinson PM, de Mulder PH, et al. Equivalence of three or four cycles of bleomycin, etoposide, an cisplatin chemotherapy and a 3 or 5-day schedule in good-prognosis germ cell cancer: a randomized study of the European Organization for Research and Treatment of Cancer, Genitourinary Tract Cancer Cooperative Group, and the Medical Research Council. J Clin Oncol 2001; 19: 1629–40PubMedGoogle Scholar
  16. 16.
    Loehrer PJ, Einhorn LH, Williams SD. VP-16 plus ifosfamide plus cisplatin as salvage therapy in refractory germ cell cancer. J Clin Oncol 1986; 4: 528–36PubMedGoogle Scholar
  17. 17.
    Broun ER, Nicholas CR, Gize G, et al. Tandem high dose chemotherapy with autologous bone marrow transplantation for initial relapse of testicular germ cell cancer. Cancer 1997; 79(8): 1605–1610PubMedCrossRefGoogle Scholar
  18. 18.
    Mandanas RA, Saez RA, Epstein RB, et al. Long-term results of autologous marrow transplantation for relapsed or refractory male or female germ cell tumors. Bone Marrow Transplant 1998; 21: 569–76PubMedCrossRefGoogle Scholar
  19. 19.
    Pedersen-Bjergaard J. Therapy-related myelodysplasia and acute leukemia. Leuk Lymphoma 1995; 15: 11–2PubMedCrossRefGoogle Scholar
  20. 20.
    Bokemeyer C, Schmoll HJ. Secondary neoplasms following treatment of malignant germ cell tumors. J Clin Oncol 1993; 11: 1703–9PubMedGoogle Scholar
  21. 21.
    Kollmannsberger C, Kuzcyk M, Mayer F, et al. Late toxicity following curative treatment of testicular cancer. Semin Surg Oncol 1999; 17: 275–81PubMedCrossRefGoogle Scholar
  22. 22.
    Ratain MJ, Rowley JD. Therapy-related acute myeloid leukemia secondary to inhibitors of topoisomerase II: from the bedside to the target genes. Ann Oncol 1992; 3: 107–11PubMedCrossRefGoogle Scholar
  23. 23.
    Bokemeyer C, Freund M, Schmoll HJ, et al. Secondary lymphoblastic leukemia following treatment of a malignant germ cell tumour [letter]. Ann Oncol 1992; 3: 772PubMedGoogle Scholar
  24. 24.
    Travis LB, Holoway EJ, Bergfeldt K, et al. Risk of leukemia after platinum-based chemotherapy for ovarian cancer. N Engl J Med 1999; 340: 351–7PubMedCrossRefGoogle Scholar
  25. 25.
    Pedersen-Bjergaard J, Daugaard G, Hansen SW, et al. Increased risk of myelodysplasia and leukaemia after etoposide, cisplatin, and bleomycin for germ cell tumours. Lancet 1991; 338(8763): 359–63PubMedCrossRefGoogle Scholar
  26. 26.
    Boshoff C, Begent RH, Oliver RT, et al. Secondary tumours following etoposide containing therapy for gem cell cancer. Ann Oncol 1995; 6: 35–40PubMedGoogle Scholar
  27. 27.
    Bajorin DF, Motzer RJ, Rodriguez E, et al. Acute nonlymphocytic leukemia in germ cell tumor patients treated with etoposide-containing chemotherapy. J Natl Cancer Inst 1993; 85: 60–2PubMedCrossRefGoogle Scholar
  28. 28.
    Nichols CR, Breeden ES, Loehrer PJ, et al. Secondary leukemia associated with a conventional dose of etoposide: review of serial germ cell tumor protocols. J Natl Cancer Inst 1993; 85: 36–40PubMedCrossRefGoogle Scholar
  29. 29.
    Travis LB, Curtis RE, Storm H, et al. Risk of second malignant neoplasm among long-term survivors of testicular cancer. J Natl Cancer Inst 1997; 89: 1429–39PubMedCrossRefGoogle Scholar
  30. 30.
    Ayash LJ, Clarke M, Silver SM, et al. Double dose intensive chemotherapy with autologous stem cell support for relapsed or refractory testicular cancer: the University of Michigan experience and literature review. Bone Marrow Transplant 2001; 27: 939–47PubMedCrossRefGoogle Scholar
  31. 31.
    Pui CH, Ribeiro RC, Hancock ML, et al. Acute myeloid leukemia in children treated with epipodophyllotoxins for acute lymphoblastic leukemia. N Engl J Med 1991; 325: 1682–7PubMedCrossRefGoogle Scholar
  32. 32.
    Kollmannsberger C, Beyer J, Droz JP, et al. Secondary leukemia following high cummulative doses of etoposide in patients treated for advanced germ cell tumors. J Clin Oncol 1998; 16: 3386–91PubMedGoogle Scholar
  33. 33.
    Kollmannsberger C, Hartmann JT, Kanz L, et al. Risk of secondary myeloid leukemia and myelodysplastic syndrome following standard-dose chemotherapy or high-dose chemotherapy with stem cell support in patients with potentially curable malignancies. J Cancer Res Clin Oncol 1998; 124: 207–14PubMedCrossRefGoogle Scholar
  34. 34.
    Hartmann JT, Nichols CR, Droz JP, et al. Hematologic disorders associated with primary mediastinal nonseminomatous germ cell tumors. J Natl Cancer Inst 2000; 92: 54–61PubMedCrossRefGoogle Scholar
  35. 35.
    Nichols CR, Roth BJ, Heerema N, et al. Hematologic neoplasia associated with primary mediastinal germ-cell tumors. N Engl J Med 1990; 322: 1425–9PubMedCrossRefGoogle Scholar
  36. 36.
    Wanderas EH, Fossa SD, Tretli S. Risk of subsequent non-germ cell cancer after treatment of germ cell cancer in 2006 Norwegian male patients. Eur J Cancer 1997; 33: 253–62PubMedCrossRefGoogle Scholar
  37. 37.
    Kaldor JM, Day NE, Band P, et al. Second malignancies following testicular cancer, ovarian cancer and Hodgkin’s disease: an international collaborative study among cancer registeries. Int J Cancer 1987; 39: 571–85PubMedCrossRefGoogle Scholar
  38. 38.
    Ginsberg SJ, Comis RL. The pulmonary toxicity of antineoplastic agents. Semin Oncol 1982; 9: 34–51PubMedGoogle Scholar
  39. 39.
    Bauer KA, Skarin AT, Balikian JP, et al. Pulmonary complications associated with combination chemotherapy programs containing bleomycin. Am J Med 1983; 74: 557–63PubMedCrossRefGoogle Scholar
  40. 40.
    Blom-Muilwijk MC, Vriesendorp R, Veninga TS, et al. Pulmonary toxicity after treatment with bleomycin alone or in combination with hyperoxia. Br J Anaesth 1988; 60: 91–7PubMedCrossRefGoogle Scholar
  41. 41.
    Hirsch A, Vander Els N, Straus DJ, et al. Effect of ABVD chemotherapy with and without mantle or mediastinal irradiation on pulmonary function and symptoms in early-stage Hodgkin’s disease. J Clin Oncol 1996; 14: 1297–305PubMedGoogle Scholar
  42. 42.
    Sleijfer S, Van der Mark TW, Schraffordt Koops H, et al. Enhanced effects of bleomycin on pulmonary function assessments in patients with decreased renal function due to cisplatin. Eur J Cancer 1996; 32A: 550–2PubMedCrossRefGoogle Scholar
  43. 43.
    Yagoda A, Mukherji B, Young C, et al. Bleomycin: an antitumor antibiotic: clinical experience in 274 patients. Ann Intern Med 1972; 77: 861–70PubMedGoogle Scholar
  44. 44.
    Lower EE, Strohofer S, Baughman RP. Bleomycin causes alveolar macrophages from cigarette smokers to release hydrogen peroxide. Am J Med Sci 1988; 295: 193–7PubMedCrossRefGoogle Scholar
  45. 45.
    Collis CH. Lung damage of cytotoxic drugs. Cancer Chemother Pharmacol 1980; 4: 17–27PubMedCrossRefGoogle Scholar
  46. 46.
    Wilson KS, Worth SA, Richards AG, et al. Low-dose bleomycin lung. Med Pediatr Oncol 1982; 10: 283–8PubMedCrossRefGoogle Scholar
  47. 47.
    Tryka AF, Skornik WA, Godleski JJ, et al. Potentiation of bleomycin-induced lung injury by exposure to 70% oxygen. Am Rev Respir Dis 1982; 126: 1074–6PubMedGoogle Scholar
  48. 48.
    Donat SM, Levy DA. Bleomycin associated pulmonary toxicity: is perioperative oxygen restriction necessary? J Urol 1998; 160: 1347–52PubMedCrossRefGoogle Scholar
  49. 49.
    White DA, Stover DE. Severe bleomycin-induced pneumonitis: clinical features and response to corticosteroids. Chest 1984; 86: 723–8PubMedCrossRefGoogle Scholar
  50. 50.
    Comis RL. Detecting bleomycin pulmonary toxicity: a continued conundrum. J Clin Oncol 1990; 8: 765–7PubMedGoogle Scholar
  51. 51.
    Sleijfer S, Van der Mark TW, Schraffordt Koops H, et al. Decrease in pulmonary function during bleomycin-containing combination chemotherapy for testicular cancer: not only a bleomycin effect. Br J Cancer 1995; 71: 120–3PubMedCrossRefGoogle Scholar
  52. 52.
    Maher J, Daley PA. Severe bleomycin lung toxicity: reversal with high dose corticosteroids. Thorax 1993; 48: 92–4PubMedCrossRefGoogle Scholar
  53. 53.
    Fossa SD, Lehne G, Heimdal K, et al. Clinical and biochemical long-term toxicity after postoperative cisplatin-based chemotherapy in patients with low-stage testicular cancer. Oncology 1995; 52: 300–5PubMedCrossRefGoogle Scholar
  54. 54.
    Vogelzang NJ, Bosl GJ, Johnson K, et al. Raynaud’s phenomenon: a common toxicity after combination chemotherapy for testicular cancer. Ann Intern Med 1981; 95: 288–92PubMedGoogle Scholar
  55. 55.
    Vogelzang NJ, Torkelson JL, Kennedy BJ. Hypomagnesemia, renal dysfunction, and Raynaud’s phenomenon in patients treated with cisplatin, vinblastine, and bleomycin. Cancer 1985; 56: 2765–70PubMedCrossRefGoogle Scholar
  56. 56.
    Stoter G, Koopman A, Vendrik CP, et al. Ten-year survival and late sequelae in testicular cancer patients treated with cisplatin, vinblastine, and bleomycin. J Clin Oncol 1989; 7: 1099–104PubMedGoogle Scholar
  57. 57.
    Boyer M, Raghavan D, Harris PJ, et al. Lack of late toxicity in patients treated with cisplatin-containing combination chemotherapy for metastatic testicular cancer. J Clin Oncol 1990; 8: 21–6PubMedGoogle Scholar
  58. 58.
    Meinardi MT, Gietema JA, van Veldhuisen DJ, et al. Treatment related cardiovascular morbidity in long-term survivors of metastatic testicular cancer. J Clin Oncol 2000; 18: 1725–32PubMedGoogle Scholar
  59. 59.
    Bokemeyer C, Berger CC, Kuczyk MA, et al. Evaluation of long-term toxicity after chemotherapy for testicular cancer. J Clin Oncol 1996; 14: 2923–32PubMedGoogle Scholar
  60. 60.
    Adoue D, Arlet P. Bleomycin and Raynaud’s phenomenon [letter]. Ann Intern Med 1984; 100: 770PubMedGoogle Scholar
  61. 61.
    Doll D, List A, Greco F, et al. Acute vascular ischemic events after cisplatin-based combination chemotherapy for germ-cell tumors of the testis. Ann Intern Med 1986; 105: 48–51PubMedGoogle Scholar
  62. 62.
    Icli F, Karaoguz H, Dincol D, et al. Severe vascular toxicity associated with cisplatin-based chemotherapy. Cancer 1993; 72: 587–93PubMedCrossRefGoogle Scholar
  63. 63.
    Rodriguez J, Collazos J, Gallardo M, et al. Angina pectoris following cisplatin, etoposide, and bleomycin in a patient with advanced testicular cancer. Ann Pharmacother 1995; 29: 138–9PubMedGoogle Scholar
  64. 64.
    Samules BL, Vogelzang NJ, Kennedy BJ. Severe vascular toxicity associated with vinblastine, bleomycin, and ciplatin chemotherapy. Cancer Chemother Pharmacol 1987; 19: 253–6Google Scholar
  65. 65.
    Lajer H, Daugaard G. Cisplatin and hypomagnesemia. Cancer Treat Rev 1999; 25: 47–58PubMedCrossRefGoogle Scholar
  66. 66.
    Turlapaty PD, Altura BM. Magnesium deficiency produces spasms of coronary arteries: relationship to etiology of sudden death ischemic heart disease. Science 1980; 208: 198–200PubMedCrossRefGoogle Scholar
  67. 67.
    Licciardello JT, Moake JL, Rudy CK, et al. Elevated plasma von Willebrand factor levels and arterial occlusive complications associated with cisplatin-based chemotherapy. Oncology 1985; 42: 296–300PubMedCrossRefGoogle Scholar
  68. 68.
    Raghavan D, Cox K, Childs A, et al. Hypercholesterolemia after chemotherapy for testis cancer. J Clin Oncol 1992; 10: 1386–9PubMedGoogle Scholar
  69. 69.
    Ellis PA, Fitzharris BM, George PM, et al. Fasting plasma lipid measurements following cisplatin chemotherapy in patients with germ cell tumors. J Clin Oncol 1992; 10: 1609–14PubMedGoogle Scholar
  70. 70.
    Strumberg D, Brugge S, Korn MW, et al. Evaluation of long-term toxicity in patients after cisplatin-based chemotherapy for non-seminomatous testicular cancer. Ann Oncol 2002; 13: 229–36PubMedCrossRefGoogle Scholar
  71. 71.
    Huddart RA, Shahidi NM, Coward HD, et al. Cardiovascular disease as a long-term complication of treatment for testicular cancer. Cancer J Clin Oncol 2003; 21: 1513–23Google Scholar
  72. 72.
    Lejonc JL, Vernant JP, Macquin J, et al. Myocardial infarction following vinblastine treatment [letter]. Lancet 1980; II: 692CrossRefGoogle Scholar
  73. 73.
    Airey C, Dodwell D, Joffe J, et al. Etoposide-related myocardial infarction. Clin Oncol (R Coll Radiol) 1995; 7: 135CrossRefGoogle Scholar
  74. 74.
    Thompson SW, Davis LE, Kornfeld M, et al. Cisplatin neuropathy: clinical, electrophysiologic, morphologic, and toxicologic studies. Cancer 1984; 54: 1269–75PubMedCrossRefGoogle Scholar
  75. 75.
    Hartmann JT, Kollmannsberger C, Kanz L, et al. Platinum organ toxicity and possible prevention in patients with testicular cancer. Int J Cancer 1999; 83: 866–9PubMedCrossRefGoogle Scholar
  76. 76.
    Hansen SW, Helweg-Larsen S, Trojaborg W. Long-term neurotoxicity in patients treated with cisplatin, vinblastine, and bleomycin for metastatic germ cell cancer. J Clin Oncol 1989; 7: 1457–61PubMedGoogle Scholar
  77. 77.
    Roth BJ, Griest A, Kubilis PS, et al. Cisplatin-based combination chemotherapy for disseminated germ cell tumors: long-term follow-up. J Clin Oncol 1988; 6: 1239–47PubMedGoogle Scholar
  78. 78.
    Van Der Hulst RJ, Dreschler WA, Urbanus NA. High frequency audiometry in prospective clinical research of ototoxicity due to platinum derivatives. Ann Otol Rhinol Laryngol 1988; 97: 133–7PubMedGoogle Scholar
  79. 79.
    Bokemeyer C, Berger CC, Hartmann JT, et al. Analysis of risk factors for cisplatin-induced ototoxicity in patients with testicular cancer. Br J Cancer 1998; 77: 1355–62PubMedCrossRefGoogle Scholar
  80. 80.
    Gonzales-Vitale JC, Hayes DM, Cvitkovic E, et al. The renal pathology in clinical trials of cis-platinum (II) diammine-dichloride. Cancer 1977; 39: 1362–71PubMedCrossRefGoogle Scholar
  81. 81.
    Dentino M, Luft FC, Yum MN, et al. Long term effect of cisdiamminedichloride platinum (CDDP) on renal function and structure in man. Cancer 1978; 41: 1274–81PubMedCrossRefGoogle Scholar
  82. 82.
    Fjeldborg P, Sorensen JB, Helkjaer PE, et al. The long-term effect of cisplatin on renal function. Cancer 1986; 58: 2214–7PubMedCrossRefGoogle Scholar
  83. 83.
    Osanto S, Bukman A, Van Hoek F, et al. Long-term effects of chemotherapy in patients with testicular cancer. J Clin Oncol 1992; 10: 574–9PubMedGoogle Scholar
  84. 84.
    Moul JW, Robertson JE, George SL, et al. Complications of therapy for testicular cancer. J Urol 1989; 142: 1491–6PubMedGoogle Scholar
  85. 85.
    Hartmann JT, Fels LM, Knop S, et al. A randomized trial comparing the nephrotoxicity of cisplatin/ifosfamide-based combination chemotherapy with or without amifostine in patients with solid tumors. Invest New Drugs 2000; 18: 281–9PubMedCrossRefGoogle Scholar
  86. 86.
    Hartmann JT, von Vangerow A, Fels LM, et al. A randomized trial of amifostine in patients with high-dose VIC chemotherapy plus autologous blood stem cell transplantation. Br J Cancer 2001; 84: 313–20PubMedCrossRefGoogle Scholar
  87. 87.
    Bajorin DF, Sarosdy MF, Pfister DG, et al. Randomized trial of etoposide and cisplatin versus etoposide and carboplatin in patients with good-risk germ cell tumors: a multiinstitutional study. J Clin Oncol 1993; 11: 598–606PubMedGoogle Scholar
  88. 88.
    Horwich A, Sleijfer DT, Fossa SD, et al. Randomized trial of bleomycin, etoposide, and cisplatin compared with bleomycin, etoposide, and carboplatin in good-prognosis metastatic nonseminomatous germ cell cancer: a multiinstitutional medical research council/European organization for research and treatment of cancer trial. J Clin Oncol 1997; 15: 1844–52PubMedGoogle Scholar
  89. 89.
    Petersen PM, Skakkebaek NE, Vistisen K, et al. Semen quality and reproductive hormones before orchiectomy in men with testicular cancer. J Clin Oncol 1999; 17: 941–7PubMedGoogle Scholar
  90. 90.
    Turek PJ, Lowther DN, Carroll PR. Fertility issues and their management in men with testis cancer. Urol Clin North Am 1998; 25: 517–31PubMedCrossRefGoogle Scholar
  91. 91.
    Aass N, Fossa SD, Theodorsen L, et al. Prediction of long term gonadal toxicity after standard treatment for testicular cancer. Eur J Cancer 1991; 27: 1087–91PubMedCrossRefGoogle Scholar
  92. 92.
    Jacobsen KD, Theodorsen L, Fossa SD. Spermatogenesis after unilateral orchiectomy for testicular cancer in patients following surveillance policy. J Urol 2001; 165: 93–6PubMedCrossRefGoogle Scholar
  93. 93.
    Boyer M, Raghavan D. Toxicity of treatment of germ cell tumors. Semin Oncol 1992; 19: 128–42PubMedGoogle Scholar
  94. 94.
    de Santis M, Albrecht W, Holtl W, et al. Impact of cytotoxic treatment on long-term fertility in patients with germ-cell cancer. Int J Cancer 1999; 83: 864–5CrossRefGoogle Scholar
  95. 95.
    Hansen PV, Hansen SW. Gonadal function in men with testicular germ cell cancer: the influence of cisplatin-based chemotherapy. Eur Urol 1993; 23: 153–6PubMedGoogle Scholar
  96. 96.
    Lampe HH, Nicholls J, Dearnaley DP. Fertility after chemotherapy for testicular germ cell cancers. J Clin Oncol 1997; 15: 239–45PubMedGoogle Scholar
  97. 97.
    Hansen SW, Berthelsen JG, van der Maase H. Long-term fertility and Leydig cell function in patients treated for germ cell cancer with cisplatin, vinblastine, and bleomycin versus surveillance. J Clin Oncol 1990; 8: 1695–8PubMedGoogle Scholar

Copyright information

© Adis Data Information BV 2003

Authors and Affiliations

  1. 1.Department of Medicine, Division of Hematology/OncologyMedical University of South CarolinaCharlestonUSA

Personalised recommendations